“Sunshine” policy, aimed at making financial ties between health professionals and industry publicly transparent, has recently gone global. Given that transparency is not the sole means of managing conflict of interest, and is unlikely to be effective on its own, it is important to understand why disclosure has emerged as a predominant public policy solution, and what the effects of this focus on transparency might be. We used Carol Bacchi’s problem-questioning approach to policy analysis to compare the Sunshine policies in three different jurisdictions, the United States, France and Australia. We found that transparency had emerged as a solution to several different problems including misuse of tax dollars, patient safety and public trust....
Abstract Financial conflicts of interest exist between industry and physicians, and these relations...
Authors of clinical practice guidelines (CPGs) disclose financial conflicts of interest (FCOIs) to p...
Background Weak governance over public sector pharmaceutical policy and practice limits access to es...
"Sunshine" policy, aimed at making financial ties between health professionals and industr...
Relationships between health professionals and pharmaceutical manufacturers can unduly influence cli...
Abstract Relationships between health professionals and pharmaceutical manufacturers can unduly inf...
Transparency has become one of the primary themes in health care reform efforts in the United States...
International audienceThis chapter examines the politics of transparency through the case of a gover...
The Physician Payments Sunshine Act (PPSA) requires health care product manufacturers to report to t...
© Copyright 2017 Wolters Kluwer Health, Inc. Objectives: There is a growing expectation in health sy...
The issue of open disclosure has received growing attention from policy-makers, legal experts and ac...
Requiring hospitals to inform patients of clinical best practices and to disclose performance data a...
Context: Conflicts of interest (CoIs) are considered to be ubiquitous in health care and biomedicine...
Background: Conflicts of interest are considered to be ubiquitous in healthcare and biomedicine. Dis...
The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the ne...
Abstract Financial conflicts of interest exist between industry and physicians, and these relations...
Authors of clinical practice guidelines (CPGs) disclose financial conflicts of interest (FCOIs) to p...
Background Weak governance over public sector pharmaceutical policy and practice limits access to es...
"Sunshine" policy, aimed at making financial ties between health professionals and industr...
Relationships between health professionals and pharmaceutical manufacturers can unduly influence cli...
Abstract Relationships between health professionals and pharmaceutical manufacturers can unduly inf...
Transparency has become one of the primary themes in health care reform efforts in the United States...
International audienceThis chapter examines the politics of transparency through the case of a gover...
The Physician Payments Sunshine Act (PPSA) requires health care product manufacturers to report to t...
© Copyright 2017 Wolters Kluwer Health, Inc. Objectives: There is a growing expectation in health sy...
The issue of open disclosure has received growing attention from policy-makers, legal experts and ac...
Requiring hospitals to inform patients of clinical best practices and to disclose performance data a...
Context: Conflicts of interest (CoIs) are considered to be ubiquitous in health care and biomedicine...
Background: Conflicts of interest are considered to be ubiquitous in healthcare and biomedicine. Dis...
The European pharmaceutical industry uses the alleged efficacy of self-regulation to question the ne...
Abstract Financial conflicts of interest exist between industry and physicians, and these relations...
Authors of clinical practice guidelines (CPGs) disclose financial conflicts of interest (FCOIs) to p...
Background Weak governance over public sector pharmaceutical policy and practice limits access to es...